Recurrent Mantle Cell Lymphoma Terminated Phase 2 Trials for Lenalidomide (DB00480)

Also known as: Mantle Cell Lymphoma Recurrent

IndicationStatusPhase
DBCOND0028615 (Recurrent Mantle Cell Lymphoma)Terminated2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01419795Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, or Non-Hodgkin Lymphoma Previously Treated With Donor Stem Cell TransplantTreatment